![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Show more
- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license...
Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.63 | 32.9842931937 | 1.91 | 3.72 | 1.8 | 9614415 | 2.45265026 | CS |
4 | 0.59 | 30.2564102564 | 1.95 | 3.72 | 1.79 | 5929006 | 2.22363109 | CS |
12 | 1.675 | 193.641618497 | 0.865 | 3.72 | 0.7436 | 8096589 | 1.87427685 | CS |
26 | 2.1149 | 497.506469066 | 0.4251 | 3.72 | 0.304 | 10922022 | 1.14099332 | CS |
52 | 2.15 | 551.282051282 | 0.39 | 3.72 | 0.304 | 6538291 | 1.07215389 | CS |
156 | -5.2649 | -67.456341529 | 7.8049 | 8.65 | 0.2911 | 3329871 | 1.71103882 | CS |
260 | -5.89 | -69.8695136418 | 8.43 | 19.43 | 0.2911 | 2654389 | 3.91339909 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions